Amedeo Smart

Free Medical Literature Service



Drug Resistance

  Free Subscription

Articles published in
    February 2021
  1. MCCLUSKEY SM, Kamelian K, Musinguzi N, Kigozi S, et al
    Pre-treatment integrase inhibitor resistance is uncommon in ART-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
    AIDS. 2021 Feb 23. pii: 00002030-900000000-96475.
    >> Share

  2. LI Y, Etemad B, Dele-Oni R, Sharaf R, et al
    Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.
    AIDS. 2021 Feb 22. pii: 00002030-900000000-96478.
    >> Share

  3. ANDERSSON E, Ambikan A, Brannstrom J, Aralaguppe SG, et al
    High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden.
    AIDS. 2021;35:227-234.
    >> Share

    December 2020
  4. MONACO DC, Zapata L, Hunter E, Salomon H, et al
    Resistance profile of HIV-1 quasispecies in patients under treatment failure using single molecule, real-time sequencing.
    AIDS. 2020;34:2201-2210.
    >> Share

    November 2020
  5. MUCCINI C, Spagnuolo V, Canetti D, Bigoloni A, et al
    Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance.
    AIDS. 2020;34:2152-2155.
    >> Share

    October 2020
  6. BAJEMA KL, Nance RM, Delaney JAC, Eaton E, et al
    Significant decline in heavily treatment experienced persons with HIV with limited antiretroviral treatment options in the US, 2000-2017.
    AIDS. 2020 Oct 12. doi: 10.1097/QAD.0000000000002679.
    >> Share

  7. BENNETT SJ, Chunda-Liyoka C, Poppe LK, Meinders K, et al
    High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs.
    AIDS. 2020;34:1833-1842.
    >> Share

    September 2020
  8. YOTSUMOTO M, Hachiya A, Ichiki A, Amano K, et al
    Second-generation integrase strand inhibitors can be effective against elvitegravir-derived multiple integrase gene substitutions.
    AIDS. 2020 Sep 14. doi: 10.1097/QAD.0000000000002688.
    >> Share

    August 2020
  9. GAY CL, Neo DT, Devanathan AS, Kuruc JD, et al
    Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.
    AIDS. 2020 Aug 7. doi: 10.1097/QAD.0000000000002652.
    >> Share

  10. INZAULE SC, Bertagnolio S, Kityo CM, Siwale M, et al
    The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa.
    AIDS. 2020;34:1559-1566.
    >> Share

    July 2020
  11. GIATSOU E, Abdi B, Plu I, Desire N, et al
    Ultradeep sequencing reveals HIV-1 diversity and resistance compartmentalization during HIV-encephalopathy.
    AIDS. 2020 Jul 21. doi: 10.1097/QAD.0000000000002616.
    >> Share

  12. INZAULE SC, Jordan MR, Cournil A, Giron-Callejas A, et al
    Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low- and middle-income countries.
    AIDS. 2020 Jul 17. doi: 10.1097/QAD.0000000000002623.
    >> Share

    May 2020
  13. INZAULE SC, Jordan MR, Bello G, Wadonda-Kabondo N, et al
    High levels of resistance to nucleoside/nucleotide reverse transcriptase inhibitors in newly-diagnosed antiretroviral treatment naive children in sub-Saharan Africa.
    AIDS. 2020 May 20. doi: 10.1097/QAD.0000000000002580.
    >> Share

    March 2020
  14. PANPRADIST N, Beck IA, Ruth PS, Avila-Rios S, et al
    Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
    AIDS. 2020 Mar 19. doi: 10.1097/QAD.0000000000002524.
    >> Share

  15. JAMES CW, Szabo S, Kahal D, Goldstein ND, et al
    The effect of multivitamins and polyvalent cations on virologic suppression with integrase strand transfer inhibitors.
    AIDS. 2020;34:487-489.
    >> Share

    December 2019
  16. YE J, Hao M, Xing H, Zhang F, et al
    Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: A multicenter observational study.
    AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002468.
    >> Share

  17. SALOU M, Butel C, Comlan AS, Konou AA, et al
    Challenges of scale-up to Dolutegravir based regimens in sub-Saharan Africa: a case study in Togo.
    AIDS. 2019 Dec 27. doi: 10.1097/QAD.0000000000002470.
    >> Share

    November 2019
  18. MORANGUINHO I, Borrego P, Goncalves F, Gomes P, et al
    Genotypic resistance profiles of HIV-2 infected patients from Cape Verde failing first-line antiretroviral therapy.
    AIDS. 2019 Nov 14. doi: 10.1097/QAD.0000000000002431.
    >> Share

    October 2019
  19. FOGEL JM, Sivay MV, Cummings V, Wilson EA, et al
    HIV drug resistance in a cohort of HIV-infected men who have sex with men in the United States.
    AIDS. 2019 Oct 10. doi: 10.1097/QAD.0000000000002394.
    >> Share

  20. LIU L, Dai L, Yao J, Pan P, et al
    Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naive individuals in a tertiary care hospital in Beijing, China.
    AIDS. 2019;33:1945-1947.
    >> Share

    September 2019
  21. KOUAMOU V, Manasa J, Katzenstein D, McGregor AM, et al
    Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
    AIDS. 2019;33:1729-1737.
    >> Share

    May 2019
  22. INZAULE SC, Mr J, Cournil A, Vitoria M, et al
    Increasing levels of pretreatment HIV drug resistance and safety concerns for dolutegravir use in women of reproductive age: a double setback.
    AIDS. 2019 May 29. doi: 10.1097/QAD.0000000000002277.
    >> Share

  23. AMBROSIONI J, Rico JAF, Nicolas D, Mosquera MM, et al
    E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection.
    AIDS. 2019 May 6. doi: 10.1097/QAD.0000000000002243.
    >> Share

  24. MOYO S, Gaseitsiwe S, Zahralban-Steele M, Maruapula D, et al
    Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
    AIDS. 2019;33:1073-1082.
    >> Share

  25. MILNE RS, Silverman RA, Beck IA, Mckernan-Mullin J, et al
    Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.
    AIDS. 2019;33:941-951.
    >> Share

    April 2019
  26. ALESSANDRI-GRADT E, Unal G, Leoz M, Plantier JC, et al
    Virological response to INSTI-based antiretroviral combinations in HIV-1 group O infected patients.
    AIDS. 2019 Apr 3. doi: 10.1097/QAD.0000000000002215.
    >> Share

    December 2018
  27. TODESCO E, Wirden M, Calin R, Simon A, et al
    Caution is needed in interpreting HIV transmission chains by ultra-deep sequencing.
    AIDS. 2018 Dec 21. doi: 10.1097/QAD.0000000000002105.
    >> Share

    October 2018
  28. ZUCKERMAN NS, Mor Z, Bucris E, Wax M, et al
    Sexual intermingling of arab and jewish men who have sex with men in israel: results of a molecular epidemiology study.
    AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002057.
    >> Share

  29. SCHULTZE A, Torti C, Cozzi-Lepri A, Vandamme AM, et al
    The effect of primary drug resistance on CD4 cell decline and the viral load set-point in HIV positive individuals before the start of antiretroviral therapy.
    AIDS. 2018 Oct 15. doi: 10.1097/QAD.0000000000002046.
    >> Share

    September 2018
  30. KENYON C
    We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia/gonorrhoea in PrEP cohorts.
    AIDS. 2018 Sep 17. doi: 10.1097/QAD.0000000000002020.
    >> Share

    August 2018
  31. DAVY-MENDEZ T, Eron JJ, Brunet L, Zakharova O, et al
    New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations.
    AIDS. 2018 Aug 20. doi: 10.1097/QAD.0000000000001990.
    >> Share

  32. KANTOR R, Delong A, Schreier L, Reitsma M, et al
    HIV Second-Line Failure and Drug Resistance at High- and Low-Level Viremia in Western Kenya.
    AIDS. 2018 Aug 20. doi: 10.1097/QAD.0000000000001964.
    >> Share

  33. DELAUGERRE C, Rodriguez C, Capitant C, Nere ML, et al
    Drug resistance among patients who acquired HIV infection in a PrEP trial.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001960.
    >> Share

  34. ZHANG X, Ding X, Zhu Y, Chong H, et al
    Structural and functional characterization of HIV-1 cell fusion inhibitor T20.
    AIDS. 2018 Aug 8. doi: 10.1097/QAD.0000000000001979.
    >> Share

    July 2018
  35. DUARTE HA, Beck IA, Levine M, Kiptinness C, et al
    Implementation of a point mutation assay for HIV drug resistance testing in Kenya: performance, challenges, and cost.
    AIDS. 2018 Jul 12. doi: 10.1097/QAD.0000000000001934.
    >> Share

    June 2018
  36. GRAYHACK C, Sheth A, Kirby O, Davis J, et al
    Evaluating outcomes of mother-infants pairs using dolutegravir for HIV treatment during pregnancy.
    AIDS. 2018 Jun 25. doi: 10.1097/QAD.0000000000001931.
    >> Share

  37. LOUREIRO RV, Costa MN, Germano I, Calinas F, et al
    Pseudoresistance of hepatitis B virus to tenofovir with emtricitabine.
    AIDS. 2018;32:1387-1388.
    >> Share

  38. ZHANG Y, Fogel JM, Guo X, Clarke W, et al
    Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa.
    AIDS. 2018;32:1301-1306.
    >> Share

  39. OSMAN N, Mesplede T, Oliveira M, Hassounah S, et al
    Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001903.
    >> Share

  40. SEATLA KK, Avalos A, Moyo S, Mine M, et al
    Four class drug resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir based antiretroviral therapy in Botswana.
    AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001920.
    >> Share

    May 2018
  41. WOODSON E, Goldberg A, Michelo C, Basu D, et al
    HIV transmission in Discordant Couples in Africa in the context of ART availability.
    AIDS. 2018 May 11. doi: 10.1097/QAD.0000000000001871.
    >> Share

    April 2018
  42. THADEN JT, Gandhi M, Okochi H, Hurt CB, et al
    Seroconversion on PrEP: a case report with segmental hair analysis for timed adherence determination.
    AIDS. 2018 Apr 19. doi: 10.1097/QAD.0000000000001825.
    >> Share

    February 2018
  43. RIPAMONTI D, Zazzi M
    Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from the MODIBIP study.
    AIDS. 2018 Feb 8. doi: 10.1097/QAD.0000000000001776.
    >> Share

    January 2018
  44. ANDERSSON E, Nordquist A, Esbjornsson J, Flamholc L, et al
    Increase in transmitted drug resistance in migrants from Sub Saharan Africa diagnosed with HIV-1 in Sweden.
    AIDS. 2018 Jan 24. doi: 10.1097/QAD.0000000000001763.
    >> Share

    December 2017
  45. NEOGI U, Singh K, Aralaguppe SG, Rogers LC, et al
    Ex vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV-1 non-B subtypes.
    AIDS. 2017 Dec 12. doi: 10.1097/QAD.0000000000001726.
    >> Share

    November 2017
  46. LODI S, Gunthard HF, Dunn D, Garcia F, et al
    Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.
    AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001692.
    >> Share

  47. INZAULE SC, Hamers RL, Calis J, Boerma R, et al
    When prevention of mother-to-child HIV transmission fails: preventing pretreatment drug resistance in African children.
    AIDS. 2017 Nov 10. doi: 10.1097/QAD.0000000000001696.
    >> Share

  48. OLSON A, Bannert N, Sonnerborg A, de Mendoza C, et al
    Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort.
    AIDS. 2017 Nov 2. doi: 10.1097/QAD.0000000000001689.
    >> Share

    October 2017
  49. MENZA TW, Billock R, Samoff E, Eron JJ, et al
    Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016.
    AIDS. 2017;31:2235-2244.
    >> Share

  50. TARTAGLIA A, Ferrara SM, Sica S, Santantonio T, et al
    Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS. 2017;31:2314-2315.
    >> Share

    August 2017
  51. POPPE LK, Chunda-Liyoka C, Kwon EH, Gondwe C, et al
    HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens.
    AIDS. 2017;31:1885-1889.
    >> Share

    June 2017
  52. GATANAGA H, Brumme ZL, Adland E, Reyes-Teran G, et al
    Potential for immune-driven viral polymorphisms to compromise antiretroviral-based pre-exposure prophylaxis for prevention of HIV-1 infection.
    AIDS. 2017 Jun 23. doi: 10.1097/QAD.0000000000001575.
    >> Share

    April 2017
  53. INZAULE SC, Hamers RL, Mukui I, Were K, et al
    Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya.
    AIDS. 2017 Apr 10. doi: 10.1097/QAD.0000000000001500.
    >> Share

  54. LEPIK KJ, Harrigan PR, Yip B, Wang L, et al
    Emergent drug resistance with integrase strand transfer inhibitor-based regimens: Incidence and risk factors.
    AIDS. 2017 Apr 3. doi: 10.1097/QAD.0000000000001494.
    >> Share

    March 2017
  55. KANTHULA R, Rossouw T, Feucht UD, Van Dyk G, et al
    Persistence of HIV-drug-resistance among South African Children given Nevirapine to Prevent Mother-to-Child-Transmission.
    AIDS. 2017 Mar 15. doi: 10.1097/QAD.0000000000001446.
    >> Share

    January 2017
  56. NEWSUM AM, Ho CK, Lieveld FI, van de Laar TJ, et al
    The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    AIDS. 2017;31:105-112.
    >> Share

    November 2016
  57. KUNKEL A, Crawford FW, Shepherd J, Cohen T, et al
    Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
    AIDS. 2016;30:2715-2723.
    >> Share

  58. BRENNER B, Wainberg MA
    We need to use the best antiretroviral drugs worldwide to prevent HIV drug resistance.
    AIDS. 2016;30:2725-2727.
    >> Share

    September 2016
  59. MURI L, Gamell A, Ntamatungiro AJ, Glass TR, et al
    Development of HIV drug resistance and therapeutic failure in children and adolescents in rural tanzania - an emerging public health concern.
    AIDS. 2016.
    >> Share

  60. VILLABONA-ARENAS CJ, Vidal N, Guichet E, Serrano L, et al
    In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa.
    AIDS. 2016.
    >> Share

    June 2016
  61. OLIVEIRA M, Ibanescu RI, Pham HT, Brenner B, et al
    The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
    AIDS. 2016.
    >> Share

  62. HARPER K
    The emergence of acquired HIV-1 drug resistance has almost been stopped in Switzerland.
    AIDS. 2016.
    >> Share

  63. DUARTE F, Miranda AC, Peres S, Diogo I, et al
    Transmitted drug resistance in drug-naive HIV-2 infected patients.
    AIDS. 2016;30:1687-8.
    >> Share

    April 2016
  64. MUSIIME V, Kasirye P, Naidoo-James B, Nahirya-Ntege P, et al
    Once versus twice daily abacavir and lamivudine in African children: The randomised controlled ARROW Trial.
    AIDS. 2016.
    >> Share

  65. CHUNG MH, Silverman R, Beck IA, Yatich N, et al
    Increasing HIV-1 pre-treatment drug resistance among antiretroviral-naive adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.
    AIDS. 2016.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016